List of Besivance drug patents

Besivance is owned by Bausch And Lomb.

Besivance contains Besifloxacin Hydrochloride.

Besivance has a total of 4 drug patents out of which 0 drug patents have expired.

Besivance was authorised for market use on 28 May, 2009.

Besivance is available in suspension/drops;ophthalmic dosage forms.

Besivance can be used as method of treating ocular bacterial infections.

The generics of Besivance are possible to be released after 09 January, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8481526 BAUSCH AND LOMB Fluoroquinolone carboxylic acid molecular crystals
Jan, 2031

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8937062 BAUSCH AND LOMB Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria
Nov, 2029

(6 years from now)

US8604020 BAUSCH AND LOMB Fluoroquinolone carboxylic acid molecular crystals
Mar, 2030

(7 years from now)

US8415342 BAUSCH AND LOMB Besifloxacin ophthalmic composition for the treatment or control of infection
Nov, 2030

(7 years from now)

Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient

Market Authorisation Date: 28 May, 2009

Treatment: Method of treating ocular bacterial infections

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic